Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2011

View Archived Issues

Curacyte terminates phase III study of PHP

Results from RUBY-1 trial investigating darexaban in acute coronary syndrome reported

Phase I/II trial assesses everolimus in tuberous sclerosis complex

Preclinical data presented on dual orexin OX1/OX2 receptor antagonist developed at Merck & Co.

Gilead discloses results from evaluation of HCV NS3/NS4A inhibitor in healthy volunteers

Randomized phase II trial evaluates alfuzosin in women with voiding dysfunction

Bayer Schering Pharma discloses novel progesterone receptor antagonists

Bristol-Myers Squibb divulges new serine protease inhibitors

New acetyl-CoA carboxylase inhibitors claimed by Bayer Schering Pharma

Scientists at Ironwood Pharmaceuticals present novel agents for pain

Duloxetine blocks psychostimulant effects

New glucocorticoid receptor ligands synthesized

Shire reflects on first half of 2011

PTC Therapeutics and Genzyme restructure collaboration agreement for ataluren

SuperGen to become Astex Pharmaceuticals

Avantra Biosciences changes name to Courtagen Life Sciences

Royal DSM and Sinochem establish global joint venture

Gilead to amend clinical trials of GS-9190 in HCV infection

SkyePharma completes proof-of-concept study of SKP-1052

European Commission approves Afinitor for new indication

Trastuzumab enters phase II trial in Paget's disease

Marketing authorization filed for tesamorelin in Argentina

OXiGENE restructures clinical programs for Zybrestat and OXI-4503

Addex Pharmaceuticals regains rights to metabotropic glutamate mGlu4 receptor PAM program

Mesoblast clear to initiate phase II trial of Revascor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...